Qi-Hua Peng
Overview
Explore the profile of Qi-Hua Peng including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
119
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Peng Q, Wang C, Chen H, Zhang R, Pan Z, Lu Z, et al.
J Immunother Cancer
. 2021 Feb;
9(2).
PMID: 33579737
Background: CKLF-like MARVEL transmembrane domain-containing 6 (CMTM6), a programmed death-ligand 1 (PD-L1) regulator, is widely expressed in various tumors and regulates the immune microenvironment. However, its prognostic value remains controversial,...
2.
Wang X, Yue X, Zhang R, Liu T, Pan Z, Yang M, et al.
Clin Cancer Res
. 2019 Apr;
25(14):4567-4579.
PMID: 30979744
Purpose: Neoadjuvant chemoradiotherapy (neoCRT) is a standard treatment for locally advanced rectal cancer (LARC); however, resistance to chemoradiotherapy is one of the main obstacles to improving treatment outcomes. The goal...
3.
Huang K, Liu R, Peng Q, Li Z, Jiang L, Guo S, et al.
Urol Oncol
. 2018 Nov;
37(1):71-77.
PMID: 30446465
Purpose: There are limited therapeutic options for patients with advanced penile squamous cell carcinoma (PSCC) after chemotherapy failure. Thus, we evaluated the feasibility of salvage treatment using the epidermal growth...
4.
Li Y, Ye Z, Chen S, Pan Z, Zhou Q, Li Y, et al.
Int J Cancer
. 2017 Nov;
142(7):1379-1391.
PMID: 29164615
Rho guanine nucleotide exchange factors (RhoGEFs) are proteins that activate Rho GTPases in response to extracellular stimuli and regulate various biologic processes. ARHGEF19, one of RhoGEFs, was reported to activate...
5.
Kuang C, Fu X, Hua Y, Shuai W, Ye Z, Li Y, et al.
Cell Death Dis
. 2017 Jun;
8(6):e2874.
PMID: 28617432
Concurrent/adjuvant cisplatin-based chemoradiotherapy is regarded as the standard of treatment for locoregionally advanced nasopharyngeal carcinoma (NPC). However, patients who do not respond to cisplatin suffer, rather than benefit, from chemotherapy...